Compare Cipla with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs PROCTER & GAMBLE HEALTH - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA PROCTER & GAMBLE HEALTH CIPLA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 34.4 16.8 205.2% View Chart
P/BV x 4.9 6.8 72.0% View Chart
Dividend Yield % 0.4 7.0 6.0%  

Financials

 CIPLA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    CIPLA
Mar-20
PROCTER & GAMBLE HEALTH
Dec-18
CIPLA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs5863,549 16.5%   
Low Rs3571,301 27.4%   
Sales per share (Unadj.) Rs207.0511.4 40.5%  
Earnings per share (Unadj.) Rs18.661.3 30.3%  
Cash flow per share (Unadj.) Rs33.274.0 44.8%  
Dividends per share (Unadj.) Rs4.00440.00 0.9%  
Dividend yield (eoy) %0.818.1 4.7%  
Book value per share (Unadj.) Rs195.5927.8 21.1%  
Shares outstanding (eoy) m806.3516.60 4,857.5%   
Bonus/Rights/Conversions ESOS--  
Price / Sales ratio x2.34.7 48.0%   
Avg P/E ratio x25.339.6 64.0%  
P/CF ratio (eoy) x14.232.8 43.4%  
Price / Book Value ratio x2.42.6 92.2%  
Dividend payout %21.5717.9 3.0%   
Avg Mkt Cap Rs m379,91240,257 943.7%   
No. of employees `00025.81.1 2,279.1%   
Total wages/salary Rs m30,2701,313 2,305.9%   
Avg. sales/employee Rs Th6,459.67,486.7 86.3%   
Avg. wages/employee Rs Th1,171.21,157.6 101.2%   
Avg. net profit/employee Rs Th580.2897.2 64.7%   
INCOME DATA
Net Sales Rs m166,9498,490 1,966.4%  
Other income Rs m3,442244 1,411.2%   
Total revenues Rs m170,3918,734 1,950.9%   
Gross profit Rs m32,0601,482 2,163.9%  
Depreciation Rs m11,747211 5,561.8%   
Interest Rs m1,9740-   
Profit before tax Rs m21,7821,514 1,438.4%   
Minority Interest Rs m-4750-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m6,312563 1,122.1%   
Profit after tax Rs m14,9951,017 1,473.9%  
Gross profit margin %19.217.5 110.0%  
Effective tax rate %29.037.1 78.0%   
Net profit margin %9.012.0 75.0%  
BALANCE SHEET DATA
Current assets Rs m117,03815,343 762.8%   
Current liabilities Rs m43,9311,960 2,241.2%   
Net working cap to sales %43.8157.6 27.8%  
Current ratio x2.77.8 34.0%  
Inventory Days Days9649 196.4%  
Debtors Days Days8528 299.1%  
Net fixed assets Rs m107,4241,209 8,883.1%   
Share capital Rs m1,613166 971.4%   
"Free" reserves Rs m156,01815,235 1,024.1%   
Net worth Rs m157,63015,401 1,023.5%   
Long term debt Rs m23,6930-   
Total assets Rs m236,62617,595 1,344.9%  
Interest coverage x12.0NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.70.5 146.2%   
Return on assets %7.25.8 124.0%  
Return on equity %9.56.6 144.0%  
Return on capital %12.810.3 125.2%  
Exports to sales %33.00-   
Imports to sales %00-   
Exports (fob) Rs m55,175NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m56,0361,636 3,424.6%   
Fx outflow Rs m6,7644,368 154.9%   
Net fx Rs m49,272-2,732 -1,803.6%   
CASH FLOW
From Operations Rs m30,685-1,304 -2,353.5%  
From Investments Rs m1,04012,697 8.2%  
From Financial Activity Rs m-29,488-301 9,813.0%  
Net Cashflow Rs m2,34011,093 21.1%  

Share Holding

Indian Promoters % 16.0 0.0 -  
Foreign collaborators % 20.8 51.8 40.2%  
Indian inst/Mut Fund % 12.2 18.2 67.0%  
FIIs % 23.7 1.0 2,370.0%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 29.1 90.0%  
Shareholders   161,166 28,591 563.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   STERLING BIOTECH  PFIZER  ALKEM LABORATORIES  NEULAND LABS  SANOFI INDIA  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

CIPLA at All Time High; BSE HEALTHCARE Index Up 1.1% (Market Updates)

Apr 20, 2021 | Updated on Apr 20, 2021

CIPLA share price has hit an all time high at Rs 966 (up 0.6%). The BSE HEALTHCARE Index is up by 1.1%. Among the top gainers in the BSE HEALTHCARE Index today are CIPLA (up 0.6%) and ABBOTT INDIA (up 1.1%). The top losers include PROCTER & GAMBLE HEALTH (down 0.3%) and BIOCON (down 0.3%).

CIPLA Announces Quarterly Results (3QFY21); Net Profit Up 112.8% (Quarterly Result Update)

Feb 1, 2021 | Updated on Feb 1, 2021

For the quarter ended December 2020, CIPLA has posted a net profit of Rs 8 bn (up 112.8% YoY). Sales on the other hand came in at Rs 52 bn (up 18.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Apr 20, 2021 03:36 PM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS